Reynders McVeigh Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.09M Buy
17,904
+112
+0.6% +$6.53K 0.05% 96
2025
Q4
$960K Buy
17,792
+900
+5% +$43.3K 0.05% 101
2025
Q3
$762K Sell
16,892
-681
-4% -$31.8K 0.04% 112
2025
Q2
$813K Buy
17,573
+73
+0.4% +$3.58K 0.04% 113
2025
Q1
$1.07M Sell
17,500
-374
-2% -$21.8K 0.06% 92
2024
Q4
$1.01M Sell
17,874
-2,150
-11% -$120K 0.05% 94
2024
Q3
$1.04M Sell
20,024
-44
-0.2% -$2.06K 0.05% 95
2024
Q2
$833K Buy
20,068
+223
+1% +$9.98K 0.05% 102
2024
Q1
$1.08M Sell
19,845
-3,249
-14% -$166K 0.06% 92
2023
Q4
$1.19M Sell
23,094
-2,039
-8% -$107K 0.08% 90
2023
Q3
$1.46M Sell
25,133
-181
-0.7% -$11.1K 0.1% 81
2023
Q2
$1.62M Buy
25,314
+600
+2% +$40.2K 0.11% 79
2023
Q1
$1.71M Sell
24,714
-776
-3% -$54.7K 0.12% 76
2022
Q4
$1.83M Sell
25,490
-10
-0% -$754 0.13% 74
2022
Q3
$1.81M Sell
25,500
-1,360
-5% -$98.7K 0.14% 72
2022
Q2
$2.07M Buy
26,860
+4,346
+19% +$331K 0.16% 65
2022
Q1
$1.64M Sell
22,514
-110
-0.5% -$7.39K 0.1% 85
2021
Q4
$1.41M Sell
22,624
-673
-3% -$39.5K 0.08% 92
2021
Q3
$1.38M Sell
23,297
-3,585
-13% -$236K 0.08% 94
2021
Q2
$1.8M Sell
26,882
-1,730
-6% -$113K 0.11% 85
2021
Q1
$1.81M Sell
28,612
-1,779
-6% -$111K 0.12% 86
2020
Q4
$1.89M Sell
30,391
-2,775
-8% -$171K 0.13% 74
2020
Q3
$2M Sell
33,166
-3,591
-10% -$216K 0.15% 70
2020
Q2
$2.16M Buy
36,757
+7,635
+26% +$457K 0.19% 63
2020
Q1
$1.62M Sell
29,122
-1,982
-6% -$121K 0.18% 68
2019
Q4
$2M Buy
31,104
+4,717
+18% +$270K 0.19% 71
2019
Q3
$1.34M Buy
26,387
+2,290
+10% +$108K 0.14% 87
2019
Q2
$1.09M Sell
24,097
-1,165
-5% -$54.3K 0.12% 96
2019
Q1
$1.21M Sell
25,262
-1,387
-5% -$69.1K 0.13% 97
2018
Q4
$1.39M Sell
26,649
-650
-2% -$34.9K 0.18% 78
2018
Q3
$1.7M Sell
27,299
-240
-0.9% -$14.2K 0.2% 77
2018
Q2
$1.52M Sell
27,539
-619
-2% -$33.4K 0.19% 79
2018
Q1
$1.78M Buy
28,158
+181
+0.6% +$11.6K 0.23% 69
2017
Q4
$1.71M Sell
27,977
-794
-3% -$49.7K 0.22% 73
2017
Q3
$1.83M Buy
28,771
+305
+1% +$17.8K 0.24% 70
2017
Q2
$1.59M Buy
28,466
+223
+0.8% +$12.1K 0.21% 75
2017
Q1
$1.54M Sell
28,243
-325
-1% -$17.8K 0.21% 82
2016
Q4
$1.67M Sell
28,568
-1,200
-4% -$65.6K 0.24% 76
2016
Q3
$1.6M Buy
29,768
+137
+0.5% +$8.8K 0.23% 78
2016
Q2
$2.18M Buy
29,631
+1,494
+5% +$106K 0.32% 62
2016
Q1
$1.8M Sell
28,137
-1,000
-3% -$63.1K 0.27% 69
2015
Q4
$2M Sell
29,137
-56
-0.2% -$3.7K 0.33% 57
2015
Q3
$1.73M Buy
29,193
+400
+1% +$25.4K 0.3% 56
2015
Q2
$1.92M Sell
28,793
-200
-0.7% -$13.2K 0.31% 51
2015
Q1
$1.87M Buy
28,993
+860
+3% +$53.8K 0.32% 50
2014
Q4
$1.66M Sell
28,133
-835
-3% -$47.1K 0.29% 56
2014
Q3
$1.48M Buy
28,968
+1,048
+4% +$52.3K 0.28% 60
2014
Q2
$1.35M Sell
27,920
-543
-2% -$26.8K 0.31% 61
2014
Q1
$1.48M Buy
28,463
+1,497
+6% +$79.7K 0.35% 59
2013
Q4
$1.43M Buy
26,966
+550
+2% +$28K 0.35% 59
2013
Q3
$1.22M Sell
26,416
-100
-0.4% -$4.39K 0.34% 60
2013
Q2
$1.19M Buy
+26,516
New +$1.15M 0.35% 61

Other funds holding BMY

Reynders McVeigh Capital Management's BMY Position: Q1 2026 in Review

Reynders McVeigh Capital Management increased its Bristol-Myers Squibb (BMY) stake by 0.63% in Q1 2026, buying an estimated $6.53K and bringing the position to 17,904 shares worth $1.09M. The position accounts for 0.05% of the portfolio, ranked #96.

Reynders McVeigh Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.18M in Q2 2016. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Reynders McVeigh Capital Management held 17,904 shares of Bristol-Myers Squibb worth $1.09M as of Q1 2026.
  • Reynders McVeigh Capital Management bought 112 Bristol-Myers Squibb shares in Q1 2026, an estimated $6.53K.
  • Bristol-Myers Squibb made up 0.05% of Reynders McVeigh Capital Management's portfolio in Q1 2026, its #96 holding.
  • Reynders McVeigh Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Reynders McVeigh Capital Management's Bristol-Myers Squibb position peaked at $2.18M in Q2 2016.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.